Notification of Preliminary Results

RNS Number : 9255E

Futura Medical PLC

15 February 2018

 

For immediate release

15 February  2018

Futura Medical plc

("Futura" or "the Company")

Notification of Preliminary Results

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

There will be a webcast of the analyst presentation. If you would like to listen to the webcast, please log on to the following web address approximately 5 minutes before 11.00am on the day of results:

http://vm.buchanan.uk.com/2018/futuramedical140318/registration.htm

A recording of the webcast will also be made available at www.futuramedical.com following the results meeting.

For more information, or to register attendance, contact Buchanan on 020 7466 5000.

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Liz Yong	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Sophie Wills / Stephanie Watson	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

NORSFIFMLFASEIE